259 related articles for article (PubMed ID: 14720083)
1. Regulatory perspectives on data safety monitoring boards: protecting the integrity of data.
Hemmings R; Day S
Drug Saf; 2004; 27(1):1-6. PubMed ID: 14720083
[TBL] [Abstract][Full Text] [Related]
2. Sharing interim trial results by the Data Safety Monitoring Board with those responsible for the trial's conduct and progress: a narrative review.
Borg Debono V; Mbuagbaw L; Thabane L
Trials; 2017 Mar; 18(1):120. PubMed ID: 28279205
[TBL] [Abstract][Full Text] [Related]
3. Regulatory perspectives on data monitoring.
O'Neill RT
Stat Med; 2002 Oct; 21(19):2831-42. PubMed ID: 12325099
[TBL] [Abstract][Full Text] [Related]
4. Data safety and monitoring boards for African clinical trials.
Lang T; Chilengi R; Noor RA; Ogutu B; Todd JE; Kilama WL; Targett GA
Trans R Soc Trop Med Hyg; 2008 Dec; 102(12):1189-94. PubMed ID: 18644610
[TBL] [Abstract][Full Text] [Related]
5. Data monitoring committees for pragmatic clinical trials.
Ellenberg SS; Culbertson R; Gillen DL; Goodman S; Schrandt S; Zirkle M
Clin Trials; 2015 Oct; 12(5):530-6. PubMed ID: 26374679
[TBL] [Abstract][Full Text] [Related]
6. Reporting of data monitoring boards in publications of randomized clinical trials is often deficient: ACTTION systematic review.
Gewandter JS; Kitt RA; Hunsinger MR; Poku J; Lozano J; Chaudari J; Evans S; Gross RA; McDermott MP; Rowbotham MC; Turk DC; Dworkin RH
J Clin Epidemiol; 2017 Mar; 83():101-107. PubMed ID: 28126598
[TBL] [Abstract][Full Text] [Related]
7. The management of interim analyses in drug development.
Facey KM; Lewis JA
Stat Med; 1998 Aug 15-30; 17(15-16):1801-9; discussion 1811-2. PubMed ID: 9749448
[TBL] [Abstract][Full Text] [Related]
8. Data and safety monitoring policy for National Institute of Allergy and Infectious Diseases clinical trials.
Dixon DO; Weiss S; Cahill K; Fox L; Love J; McNamara J; Soto-Torres LE
Clin Trials; 2011 Dec; 8(6):727-35. PubMed ID: 22024105
[TBL] [Abstract][Full Text] [Related]
9. Data and safety monitoring during randomized controlled trials of nursing interventions.
Artinian NT; Froelicher ES; Vander Wal JS
Nurs Res; 2004; 53(6):414-8. PubMed ID: 15586138
[TBL] [Abstract][Full Text] [Related]
10. A major trial needs three statisticians: why, how and who?
Pocock SJ
Stat Med; 2004 May; 23(10):1535-9. PubMed ID: 15122734
[TBL] [Abstract][Full Text] [Related]
11. On being the statistician on a Data and Safety Monitoring Board.
Whitehead J
Stat Med; 1999 Dec; 18(24):3425-34. PubMed ID: 10611616
[TBL] [Abstract][Full Text] [Related]
12. American Society of Clinical Oncology policy statement: oversight of clinical research.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
[TBL] [Abstract][Full Text] [Related]
13. Data monitoring and interim analyses in the pharmaceutical industry: ethical and logistical considerations.
Rockhold FW; Enas GG
Stat Med; 1993 Mar; 12(5-6):471-9. PubMed ID: 8493425
[TBL] [Abstract][Full Text] [Related]
14. How to construct an optimal interim report: What the data monitoring committee does and doesn't need to know.
Neaton JD; Grund B; Wentworth D
Clin Trials; 2018 Aug; 15(4):359-365. PubMed ID: 29552920
[TBL] [Abstract][Full Text] [Related]
15. Recommendations for data monitoring committees from the Clinical Trials Transformation Initiative.
Calis KA; Archdeacon P; Bain R; DeMets D; Donohue M; Elzarrad MK; Forrest A; McEachern J; Pencina MJ; Perlmutter J; Lewis RJ
Clin Trials; 2017 Aug; 14(4):342-348. PubMed ID: 28503947
[TBL] [Abstract][Full Text] [Related]
16. Experiences and challenges in data monitoring for clinical trials within an international tropical disease research network.
Chen-Mok M; VanRaden MJ; Higgs ES; Dominik R
Clin Trials; 2006; 3(5):469-77. PubMed ID: 17060220
[TBL] [Abstract][Full Text] [Related]
17. Data Monitoring Committees: Current issues.
Fleming TR; Ellenberg SS; DeMets DL
Clin Trials; 2018 Aug; 15(4):321-328. PubMed ID: 29629815
[TBL] [Abstract][Full Text] [Related]
18. An analysis of protocols and publications suggested that most discontinuations of clinical trials were not based on preplanned interim analyses or stopping rules.
Stegert M; Kasenda B; von Elm E; You JJ; Blümle A; Tomonaga Y; Saccilotto R; Amstutz A; Bengough T; Briel M;
J Clin Epidemiol; 2016 Jan; 69():152-60. PubMed ID: 26361993
[TBL] [Abstract][Full Text] [Related]
19. Role of the data safety and monitoring board in an international trial.
NIMH Collaborative HIV/STD Prevention Trial
AIDS; 2007 Apr; 21 Suppl 2():S99-102. PubMed ID: 17413269
[TBL] [Abstract][Full Text] [Related]
20. Exploring factors associated with views on sharing of certain interim trial result measures by the data safety monitoring board (DSMB) with non-DSMB members.
Borg Debono V; Mbuagbaw L; Paul J; Buckley N; Thabane L
Trials; 2018 Nov; 19(1):621. PubMed ID: 30419939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
